Uncertainties in the relationship between bone Pb and cumulative blood lead index (CBLI), including evidence of nonlinearity and differences between the sexes, should be appropriately recognized when setting workplace blood Pb limits to achieve target bone Pb concentrations.

[@b11-ehp0116-a0109a] recommended a maximum occupational tibia Pb concentration of 15 μg/g. They stated that, based on the slope of the relationship between tibia Pb and CBLI calculated by [@b8-ehp0116-a0109a], a tibia Pb of 15 μg/g can be avoided by limiting the CBLI to \< 200--400 μg-years/dL.

[@b8-ehp0116-a0109a] acknowledged the uncertainty in the slope of the relationship between tibia Pb and CBLI. However, over the range of cumulative Pb exposures that would produce a tibia Pb concentration of 15 μg/g, the slope of the relationship between tibia Pb and CBLI may be less than the slope of 0.05 \[95% confidence interval (CI), 0.046--0.055\] μg/g per μg-years/dL calculated by [@b8-ehp0116-a0109a].

[Table 1](#t1-ehp0116-a0109a){ref-type="table"} presents slopes and mean tibia Pb concentrations among subjects of eight published studies. [@b6-ehp0116-a0109a] reported a slope of 0.022 μg/g per μg-years/dL (no uncertainty reported) and [@b1-ehp0116-a0109a] reported a slope of 0.10 (± 0.02) μg/g per μg-years/dL. These represent a greater range of slopes than reported by [@b8-ehp0116-a0109a].

These data also suggest that the tibia Pb versus CBLI slope may not be constant, with lower slopes evident for lower tibia Pb and CBLI levels. This trend has been noted previously ([@b3-ehp0116-a0109a]; [@b5-ehp0116-a0109a]). For tibia Pb concentrations of approximately 15 μg/g, a slope of approximately 0.025 μg/g per μg-years/dL seems equally plausible as the slope calculated by [@b8-ehp0116-a0109a].

A slope of 0.025 μg/g per μg-years/dL yields an allowable CBLI of 600 μg-years/dL, or an average annual blood Pb concentration of 15 μg/dL for 40 working years. This compares to 5--10 μg/dL for 40 working years associated with [@b11-ehp0116-a0109a] recommended CBLI of 200--400 μg-years/dL.

These slopes are also based on studies of predominantly male subjects and may not account for differences in Pb toxicokinetics between the sexes ([@b9-ehp0116-a0109a]; [@b10-ehp0116-a0109a]).

###### 

Various slopes of the relationship between tibia Pb and CBLI, and related mean tibia Pb concentration among study subjects.

  Study                   No.   *r*    Slope[a](#tfn1-ehp0116-a0109a){ref-type="table-fn"}   Mean Pb (μg/g tibia bone mineral)
  ----------------------- ----- ------ ----------------------------------------------------- -----------------------------------
  [@b6-ehp0116-a0109a]    100   0.60   0.022                                                 16.9
  [@b4-ehp0116-a0109a]    91    0.66   0.028 ± 0.003                                         21.1
  [@b12-ehp0116-a0109a]   79    0.86   0.050 ± 0.003                                         31.0
  [@b12-ehp0116-a0109a]   88    0.82   0.060 ± 0.005                                         32.3
  [@b2-ehp0116-a0109a]    53    0.70   0.059 ± 0.009                                         39
  [@b5-ehp0116-a0109a]    367   0.83   0.056 ± 0.002                                         40.6
  [@b7-ehp0116-a0109a]    12    0.92   0.061 ± 0.008                                         46
  [@b1-ehp0116-a0109a]    15    0.87   0.10 ± 0.02                                           54.8

Units are μg/g bone mineral per μg-year/dL.
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